Within the infection control market, Consumables held the largest share in 2025, reflecting their routine and unavoidable use across sterilization, disinfection, and contamination prevention workflows. Demand remains anchored in the recurring nature of infection control protocols, where items must be replenished continuously to support day-to-day hygiene compliance and patient safety standards. This steady replacement cycle gives Consumables a durable leadership position in the infection control market, especially because they are embedded directly into operational practice rather than tied to occasional capital purchasing decisions.

Services are emerging as the fastest-growing segment in the infection control market as healthcare and related facilities place greater emphasis on outsourced expertise, validation, and ongoing compliance support. Growth is being reinforced by the practical need to maintain consistent infection prevention performance across increasingly complex environments, where internal teams may not always have the capacity or specialized knowledge required. Compared with product-only approaches, services are gaining momentum because they help users manage implementation, monitoring, and regulatory adherence in a more continuous and structured way.

End-use Segment Analysis: Hospitals (Largest Segment) vs Medical Device Companies (Fastest-Growing Segment)

Hospitals accounted for the largest share of the infection control market in 2025, supported by the constant need to manage infection risks across high-volume patient care settings. Their leadership is maintained through the breadth of infection control requirements spanning surgical areas, intensive care units, inpatient rooms, and general clinical operations, all of which require continuous use of products and procedures designed to reduce contamination. In the infection control market, hospitals remain the leading end-use segment because infection prevention is directly tied to everyday care delivery, operational continuity, and patient outcomes.

Medical Device Companies represent the fastest-growing end-use segment in the infection control market, driven by the rising need to ensure product safety and maintain tightly controlled manufacturing and handling environments. Growth is being supported by the practical requirement to prevent contamination throughout device production and processing, where infection control measures are critical to quality assurance and regulatory compliance. Relative to more established end users, this segment is gaining pace as infection control becomes more deeply integrated into device development, production workflows, and market approval expectations.